(VIANEWS) – ELIS (ELIS.PA), X-FAB (XFAB.PA), NAVAMEDIC (NAVA.OL) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. ELIS (ELIS.PA)
77.2% sales growth and 9.02% return on equity
Elis SA provides flat linen, workwear, and hygiene and well-being solutions in France, Central Europe, Scandinavia, Eastern Europe, the United Kingdom, Ireland, Latin America, Southern Europe, and internationally. The company offers table, bed, kitchen, patient, and bath linens; workwear and personal protective equipment; beverage solutions, such as water coolers and accessories, cups and bottles, and coffee machines; floor protection mats and mops; industrial wipers; and pest and rodent control, insect control, or disinfection services. It also provides washroom hygiene services, such as hand washing and drying, toilet hygiene and urinals, lavatories, and air fragrancing; and reusable cleanroom garments, footwear, goggles, and related contamination control solutions, as well as cleaning systems. In addition, the company offers various solutions for collection and disposal of infectious waste, as well as laundry facilities. It primarily serves the catering, accommodation, healthcare and social welfare, industries, trade and retail, and services sectors, as well as public authorities and administration. Elis SA was founded in 1883 and is headquartered in Saint-Cloud, France.
Earnings Per Share
As for profitability, ELIS has a trailing twelve months EPS of €1.19.
PE Ratio
ELIS has a trailing twelve months price to earnings ratio of 14.97. Meaning, the purchaser of the share is investing €14.97 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 9.02%.
Volume
Today’s last reported volume for ELIS is 42835 which is 87.03% below its average volume of 330347.
Dividend Yield
According to Morningstar, Inc., the next dividend payment is on May 30, 2023, the estimated forward annual dividend rate is 0.41 and the estimated forward annual dividend yield is 2.66%.
Sales Growth
ELIS’s sales growth for the next quarter is 77.2%.
More news about ELIS.
2. X-FAB (XFAB.PA)
23.3% sales growth and 19.58% return on equity
X-FAB Silicon Foundries SE operates as an analog/mixed-signal semiconductor technology foundry. The company manufactures silicon wafers for automotive, industrial, consumer, medical, and mobile communications, and other applications; and analog/mixed-signal integrated circuits, sensors, and micro-electro-mechanical systems. It also provides manufacturing and design support services for customers that design analog/mixed-signal integrated circuits and other semiconductor devices, as well as engineering and prototyping, outsourcing, technical, and design support services. The company serves integrated device manufacturers, original equipment manufacturers, and fabless semiconductor companies. It operates in Belgium, Germany, the United Kingdom, Austria, France, Switzerland, Denmark, Sweden, Finland, Netherlands, Ireland, Singapore, China, Japan, Thailand, Malaysia, Korea, Taiwan, Hong Kong, New Zealand, the United States, and internationally. The company was founded in 1992 and is based in Tessenderlo, Belgium.
Earnings Per Share
As for profitability, X-FAB has a trailing twelve months EPS of €1.15.
PE Ratio
X-FAB has a trailing twelve months price to earnings ratio of 8.72. Meaning, the purchaser of the share is investing €8.72 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 19.58%.
Moving Average
X-FAB’s worth is higher than its 50-day moving average of €9.74 and higher than its 200-day moving average of €9.14.
More news about X-FAB.
3. NAVAMEDIC (NAVA.OL)
17.8% sales growth and 11.97% return on equity
Navamedic ASA, a pharmaceutical company, develops, produces, markets, and sells pharmaceuticals and related products in Northern Europe. The company's product portfolio includes prescription and non-prescription pharmaceuticals, as well as medical nutrition products, medical devices, food supplements, and cosmetics. It offers medical nutrition products for various therapeutic areas, including phenylketonuria, homocystinuria, maple syrup urine disease, tyrosinemia, methylmalonic acidemia/propionic acidemia, glutaric aciduria, isovaleric acidemia, and urea cycle disorders, as well as products for glycogen storage diseases and renal diseases, fat metabolism, malnutrition, and ketogenic diet. In addition, the company provides consumer health products consisting of non-prescription drugs and health care products for pain relief, cough and cold, gastro, obesity, women's health, and others primarily through pharmacies and drugstores; specialty pharmaceutical products in various therapeutic areas comprising dermatology, wound care, urology, and obesity; and branded generics, including cardiology products and antibiotics. It sells, markets, and distributes its products to hospitals, patients, and pharmacies. The company was formerly known as Glucomed AS and changed its name to Navamedic ASA in 2004. Navamedic ASA was incorporated in 2002 and is headquartered in Oslo, Norway.
Earnings Per Share
As for profitability, NAVAMEDIC has a trailing twelve months EPS of kr1.18.
PE Ratio
NAVAMEDIC has a trailing twelve months price to earnings ratio of 31.69. Meaning, the purchaser of the share is investing kr31.69 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 11.97%.
More news about NAVAMEDIC.
4. BOUVET (BOUV.OL)
9.7% sales growth and 60.9% return on equity
Bouvet ASA provides IT and digital communication consultancy services for public and private sector companies in Norway, Sweden, and internationally. Bouvet ASA was founded in 1995 and is based in Oslo, Norway.
Earnings Per Share
As for profitability, BOUVET has a trailing twelve months EPS of kr3.15.
PE Ratio
BOUVET has a trailing twelve months price to earnings ratio of 18.79. Meaning, the purchaser of the share is investing kr18.79 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 60.9%.
Earnings Before Interest, Taxes, Depreciation, and Amortization
BOUVET’s EBITDA is 40.45.
Revenue Growth
Year-on-year quarterly revenue growth grew by 16.5%, now sitting on 3.22B for the twelve trailing months.
More news about BOUVET.
5. AXACTOR (ACR.OL)
5.2% sales growth and 9.72% return on equity
Axactor ASA, through its subsidiaries, operates as a debt management and collection company in Sweden, Finland, Germany, Italy, Norway, and Spain. It operates through two segments: Non-performing Loans and Third-Party Collection. The Non-performing Loans segment invests in portfolios of non-performing loans collected through amicable or legal proceedings. The Third-Party Collection segment provides debt collection services on behalf of third-party clients, which applies amicable and legal proceedings to collect the non-performing loans. This segment is also involved in helping creditors to prepare documentation for future legal proceedings against debtors; and handling of invoices between the invoice date and the default date and sending out reminders. Axactor ASA was incorporated in 1982 and is headquartered in Oslo, Norway.
Earnings Per Share
As for profitability, AXACTOR has a trailing twelve months EPS of kr1.55.
PE Ratio
AXACTOR has a trailing twelve months price to earnings ratio of 3.18. Meaning, the purchaser of the share is investing kr3.18 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 9.72%.
Volume
Today’s last reported volume for AXACTOR is 80917 which is 77.57% below its average volume of 360903.
More news about AXACTOR.
